(HALO) Halozyme Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 7.961m USD | Total Return: 29% in 12m

Enzymes, Drug Delivery, Injectable Devices, Testosterone Therapy

Total Rating 69

Safety 78

Buy Signal -0.28

Biotechnology
Industry Rotation: -18.1

Market Cap: 7.96B
Avg Turnover: 98.2M

Risk 3d forecast

Volatility37.0%

VaR 5^th Pctl5.80%

VaR vs Median-5.41%

Reward TTM

Sharpe Ratio0.86

Rel. Str. IBD42.4

Rel. Str. Peer Group29.3

Character TTM

Beta0.240

Beta Downside0.194

Hurst Exponent0.640

Drawdowns 3y

Max DD33.92%

CAGR/Max DD0.79

CAGR/Mean DD2.37

EPS (Earnings per Share)

EPS CAGR: 24.93%
EPS Trend: 31.6%

Last SUE: -0.66
Qual. Beats: 0

Revenue

Rev. CAGR: 27.30%
Rev. Trend: 92.6%

Last SUE: 1.07
Qual. Beats: 1

Warnings

Choppy Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: HALO Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of drug-delivery technologies. The company’s core business model centers on its proprietary recombinant human hyaluronidase enzyme (rHuPH20), which modifies subcutaneous tissue to enhance the absorption of injected biologics and small molecules. This technology allows for the conversion of intravenous treatments into subcutaneous injections, reducing administration time for patients and healthcare providers.

The company operates primarily through a high-margin licensing and royalty model, partnering with major pharmaceutical firms including Roche, Pfizer, and Bristol Myers Squibb. By integrating rHuPH20 into existing blockbuster drugs like Darzalex and Herceptin, Halozyme generates recurring revenue streams tied to the commercial success of its partners portfolios. In the biotechnology sector, this platform-based approach often provides more diversified revenue compared to traditional single-molecule drug developers.

Halozyme’s portfolio includes internal products such as XYOSTED for testosterone replacement and Hylenex for fluid dispersion. Its collaborative pipeline spans oncology, immunology, and neuroscience, utilizing automated injector devices to expand the delivery options for complex monoclonal antibodies. For a deeper look into the companys valuation metrics and financial health, you may find further insights on ValueRay.

Headlines to Watch Out For

ENHANZE royalty revenue growth from subcutaneous Darzalex and Phesgo market adoption
Patent expiration timelines for core rHuPH20 technology impact long-term licensing income
Expansion of partner pipeline through new subcutaneous delivery collaboration agreements
Regulatory approval milestones for high-volume subcutaneous formulations of oncology biologics
Capital allocation strategy including share buybacks and strategic mergers and acquisitions

Piotroski VR‑10 (Strict) 9.0

Net Income: 348.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.25 > 0.02 and ΔFCF/TA 2.41 > 1.0
NWC/Revenue: 42.42% < 20% (prev 102.5%; Δ -60.11% < -1%)
CFO/TA 0.25 > 3% & CFO 677.4m > Net Income 348.8m
Net Debt (2.03b) to EBITDA (960.6m): 2.12 < 3
Current Ratio: 2.76 > 1.5 & < 3
Outstanding Shares: last quarter (122.9m) vs 12m ago -2.98% < -2%
Gross Margin: 76.93% > 18% (prev 0.80%; Δ 7.61k% > 0.5%)
Asset Turnover: 61.96% > 50% (prev 49.36%; Δ 12.59% > 0%)
Interest Coverage Ratio: 44.97 > 6 (EBITDA TTM 960.6m / Interest Expense TTM 19.1m)

Altman Z'' 4.27

A: 0.24 (Total Current Assets 1.00b - Total Current Liabilities 363.2m) / Total Assets 2.67b
B: 0.08 (Retained Earnings 204.8m / Total Assets 2.67b)
C: 0.35 (EBIT TTM 859.3m / Avg Total Assets 2.43b)
D: 0.08 (Book Value of Equity 192.2m / Total Liabilities 2.45b)
Altman-Z'' Score: 4.27 = AA

Beneish M -2.46

DSRI: 1.08 (Receivables 458.0m/304.6m, Revenue 1.51b/1.08b)
GMI: 1.04 (GM 76.93% / 80.17%)
AQI: 1.51 (AQ_t 0.59 / AQ_t-1 0.39)
SGI: 1.39 (Revenue 1.51b / 1.08b)
TATA: -0.12 (NI 348.8m - CFO 677.4m) / TA 2.67b)
Beneish M-Score: -2.46 (Cap -4..+1) = BBB

What is the price of HALO shares? As of May 20, 2026, the stock is trading at USD 68.73 with a total of 2,003,050 shares traded.
Over the past week, the price has changed by -3.10%, over one month by -1.21%, over three months by -4.59% and over the past year by +28.95%.

Is HALO a buy, sell or hold? Halozyme Therapeutics has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold HALO.

StrongBuy: 2
Buy: 2
Hold: 3
Sell: 1
StrongSell: 0

What are the forecasts/targets for the HALO price?

Analysts Target Price	85.4	24.3%

Halozyme Therapeutics (HALO) - Fundamental Data Overview as of 19 May 2026

P/E Trailing = 23.5509
P/E Forward = 8.8183
P/S = 5.2778
P/B = 155.6228
P/EG = -2.5
Revenue TTM = 1.51b USD
EBIT TTM = 859.3m USD
EBITDA TTM = 960.6m USD
Long Term Debt = 2.14b USD (from longTermDebt, last fiscal year)
Short Term Debt = 208.7m USD (from shortTermDebt, last quarter)
Debt = 2.35b USD (corrected: LT Debt 2.14b + ST Debt 208.7m)
Net Debt = 2.03b USD (recalculated: Debt 2.35b - CCE 318.6m)
Enterprise Value = 9.99b USD (7.96b + Debt 2.35b - CCE 318.6m)
Interest Coverage Ratio = 44.97 (Ebit TTM 859.3m / Interest Expense TTM 19.1m)
EV/FCF = 14.97x (Enterprise Value 9.99b / FCF TTM 667.7m)
FCF Yield = 6.68% (FCF TTM 667.7m / Enterprise Value 9.99b)
FCF Margin = 44.26% (FCF TTM 667.7m / Revenue TTM 1.51b)
Net Margin = 23.13% (Net Income TTM 348.8m / Revenue TTM 1.51b)
Gross Margin = 76.93% ((Revenue TTM 1.51b - Cost of Revenue TTM 348.0m) / Revenue TTM)
Gross Margin QoQ = 71.13% (prev 77.39%)
Tobins Q-Ratio = 3.74 (Enterprise Value 9.99b / Total Assets 2.67b)
Interest Expense / Debt = 0.23% (Interest Expense 5.51m / Debt 2.35b)
Taxrate = 16.79% (30.3m / 180.3m)
NOPAT = 715.0m (EBIT 859.3m * (1 - 16.79%))
Current Ratio = 2.76 (Total Current Assets 1.00b / Total Current Liabilities 363.2m)
Debt / Equity = 10.71 (Debt 2.35b / totalStockholderEquity, last quarter 219.6m)
Debt / EBITDA = 2.12 (Net Debt 2.03b / EBITDA 960.6m)
Debt / FCF = 3.04 (Net Debt 2.03b / FCF TTM 667.7m)
Total Stockholder Equity = 276.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.33% (Net Income 348.8m / Total Assets 2.67b)
RoE = 126.3% (Net Income TTM 348.8m / Total Stockholder Equity 276.3m)
RoCE = 35.52% (EBIT 859.3m / Capital Employed (Equity 276.3m + L.T.Debt 2.14b))
RoIC = 35.47% (NOPAT 715.0m / Invested Capital 2.02b)
WACC = 5.32% (E(7.96b)/V(10.31b) * Re(6.83%) + D(2.35b)/V(10.31b) * Rd(0.23%) * (1-Tc(0.17)))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -68.89 | Cagr: -2.82%
[DCF] Terminal Value 88.44% ; FCFF base≈598.9m ; Y1≈738.8m ; Y5≈1.26b
[DCF] Fair Price = 291.2 (EV 36.57b - Net Debt 2.03b = Equity 34.54b / Shares 118.6m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 31.63 | EPS CAGR: 24.93% | SUE: -0.66 | # QB: 0
Revenue Correlation: 92.60 | Revenue CAGR: 27.30% | SUE: 1.07 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.82 | Chg30d=+0.33% | Revisions=+33% | Analysts=5
EPS next Quarter (2026-09-30): EPS=2.19 | Chg30d=+0.09% | Revisions=+14% | Analysts=5
EPS current Year (2026-12-31): EPS=8.14 | Chg30d=+1.09% | Revisions=+33% | GrowthEPS=+96.1% | GrowthRev=+27.2%
EPS next Year (2027-12-31): EPS=9.84 | Chg30d=+0.33% | Revisions=-14% | GrowthEPS=+20.8% | GrowthRev=+12.4%
[Analyst] Revisions Ratio: +33%